ArticleOncogene2000
M6P/IGF2R is mutated in squamous cell carcinoma of the lung.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 105 citations in OpenAlex.
- M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis.BMC cancer · 2003Trial
- The Role of Membrane-Associated E3 Ubiquitin Ligases in Cancer.Frontiers in pharmacology · 2022Review
- Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer.Frontiers in pharmacology · 2021Review
- Article
- Maternal transmission of an Igf2r domain 11: IGF2 binding mutant allele (Igf2rScientific reports · 2019Article
- Crosstalk between Calcium and ROS in Pathophysiological Conditions.Oxidative medicine and cellular longevity · 2019Review
- Novel mutational landscapes and expression signatures of lung squamous cell carcinoma.Oncotarget · 2018Article
- Parkin and mitophagy in cancer.Oncogene · 2017Review
- Type I insulin-like growth factor receptor signaling in hematological malignancies.Oncotarget · 2017Review
- MicroRNA-19a/b mediates grape seed procyanidin extract-induced anti-neoplastic effects against lung cancer.The Journal of nutritional biochemistry · 2016Article
- WWOX, large common fragile site genes, and cancer.Experimental biology and medicine (Maywood, N.J.) · 2015Review
- Very large common fragile site genes and their potential role in cancer development.Cellular and molecular life sciences : CMLS · 2014Review
- Dominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancer.The FEBS journal · 2012Article
- Association between Gly1619ARG polymorphism of IGF2R domain 11 (rs629849) and advanced stage of oral cancer.Medical oncology (Northwood, London, England) · 2012Article
- Parkinson's disease and cancer: two wars, one front.Nature reviews. Cancer · 2011Review
- Article
- IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas.International journal of cancer · 2009Article
- IGF2R missense single-nucleotide polymorphisms and breast cancer risk: the multiethnic cohort study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2009Article
- Structure and function of the human Gly1619Arg polymorphism of M6P/IGF2R domain 11 implicated in IGF2 dependent growth.Journal of molecular endocrinology · 2009Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
In addition to the intracellular sorting of lysosomal enzymes, the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) plays a critical role in regulating the bioavailability of extracellular proteolytic enzymes and growth factors. It has also been shown to be mutated in a number of human cancers, and to suppress cancer cell growth. The purpose of this study was to determine if the M6P/IGF2R is mutated in lung cancer, a leading cause of cancer death worldwide. Archival pathology specimens were obtained on 22 patients with newly diagnosed, untreated squamous cell carcinoma of the lung. Two polymorphisms in the 3'-untranslated region of the M6P/IGF2R were used to screen lung tumors for loss of heterozygosity (LOH) by PCR amplification of DNA. Nineteen of 22 (86%) patients were informative (heterozygous), and 11/19 (58%) squamous cell carcinomas of the lung had LOH at the M6P/IGF2R locus. The remaining allele in 6/11 (55%) LOH patients contained mutations in either the mannose 6-phosphate or the IGF2 binding domain of the M6P/IGF2R. Thus, the M6P/IGF2R is mutated frequently in squamous cell carcinoma of the lung, providing further support for its function as a tumor suppressor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.